Hydrochloorthiazide Aurobindo

Hydrochloorthiazide Aurobindo is a prescription medication that contains the thiazide diuretic hydrochlorothiazide as its active ingredient. It is marketed by Aurobindo in the European Union and is supplied in oral dosage form, although the specific strength is not disclosed in the available data. The product is classified as a thiazide diuretic and is used under medical supervision for conditions requiring fluid reduction and blood‑pressure control.

Hydrochloorthiazide Aurobindo is indicated for several clinical situations in which excess fluid accumulation or elevated arterial pressure requires pharmacologic management. It is commonly prescribed as part of a broader therapeutic regimen.

- Hypertension (high blood pressure) - Edema associated with congestive heart failure - Edema secondary to liver cirrhosis - Edema related to renal disease such as nephrotic syndrome - Adjunct therapy to reduce hypercalciuria when used with calcium‑containing diuretics

Like other thiazide diuretics, Hydrochloorthiazide Aurobindo may cause a range of adverse reactions, most of which are mild and reversible.

Common: - Increased frequency of urination (polyuria) - Low blood potassium levels (hypokalemia) - Dizziness or light‑headedness, particularly when standing quickly

Serious: - Severe electrolyte imbalance (e.g., hyponatremia, hypokalemia) - Acute kidney injury or marked decline in renal function - Allergic reactions such as rash, itching, or angioedema

Before initiating Hydrochloorthiazide Aurobindo, clinicians should evaluate patient history and laboratory values to identify conditions that may increase the risk of adverse outcomes.

- Assess baseline electrolytes, renal function, and blood glucose. - Use cautiously in patients with gout or a history of hyperuricemia. - Monitor blood pressure closely during the first weeks of therapy. - Avoid in individuals with known hypersensitivity to thiazide diuretics. - Consider dose adjustment or alternative therapy in severe hepatic impairment. - Pregnant or breastfeeding women should be evaluated by a healthcare professional before use.

Hydrochlorthiazide Aurobindo can affect the pharmacokinetics or pharmacodynamics of several other medicines; awareness of key interactions helps prevent clinically significant events.

Avoid: - Concurrent use with lithium, which may increase lithium toxicity. - Co‑administration with non‑steroidal anti‑inflammatory drugs (NSAIDs) that can reduce diuretic efficacy and impair renal function. - Combining with other potent antihypertensives may cause excessive blood‑pressure lowering.

Use with caution: - Antidiabetic agents (insulin, sulfonylureas) – monitor blood glucose as the diuretic may raise glucose levels. - Cardiac glycosides (e.g., digoxin) – electrolyte shifts can increase risk of toxicity. - Corticosteroids or other diuretics – monitor electrolytes for additive effects.